re: excellent discussion I missed all the actionThe Pillman made a staggering 145000 loss over the last 5 years which I will use to settle any returns I make on shares this year and a few years beyond
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%